Trial Profile
Open Multicenter Study of Combination Therapy With Weight-Based PEG-IFN Alfa-2b [peginterferon-alfa-2b] Plus Ribavirin for Treatment of Mexican naive Patients With Chronic Hepatitis C Infected With Genotype 1. Impact of the Combination Therapy on Sustained Virological Response and Tolerability, in These Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Peginterferon alfa-2b/ribavirin (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Schering-Plough
- 18 Aug 2008 New trial record.